PHASE IB TRIAL OF IMO-2055 IN COMBINATION WITH 5-FU, CISPLATIN AND CETUXIMAB IN 1ST-LINE PTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN)

被引：0
|
作者：
Machiels, J. P. [1 ]
Kaminsky, M. C. [2 ]
Keller, U. [3 ]
Bruemmendorf, T. H. [4 ]
Goddemeier, T. [5 ]
Forssman, U. [6 ]
Delord, J. P. [7 ]
机构：
[1] Clin Univ St Luc, B-1200 Brussels, Belgium
[2] Ctr Alexis Vautrin, Dept Med Oncol, Nancy, France
[3] Tech Univ Munich, Med Klin 3, Munich, Germany
[4] Univ Klinikum Aachen, Aachen, Germany
[5] Merck KGaA, Global Clin Operat Global Biostat, Darmstadt, Germany
[6] Merck Serono SA, Global Clin Dev Unit Oncol, Geneva, Switzerland
[7] Ctr Claudius Regaud, Clin Resarch Unit, Toulouse, France
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：342 / 342
页数：1
相关论文
共 50 条
  • [31] Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): First results of phase II trial GORTEC 2008-03.
    Guigay, J.
    Fayette, J.
    Dillies, A.
    Sire, C.
    Kerger, J. N.
    Tennevet, I.
    Machiels, J. H.
    Zanetta, S.
    Pointreau, Y.
    Le Moal, L. Bozec
    Ribere, L. Brugel
    Henry, S.
    Temam, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Final results of phase II trial GORTEC 2008-03.
    Guigay, Joel
    Fayette, Jerome
    Dillies, Anne-Francoise
    Sire, Christian
    Kerger, Joseph N.
    Tennevet, Isabelle
    Machiels, Jean-Pascal H.
    Zanetta, Sylvie
    Pointreau, Yoann
    Le Moal, Laurence Bozec
    Ribere, Lydia Brugel
    Henry, Stefanie
    Temam, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)
    Choong, N. W.
    Cohen, E. E.
    Kozloff, M. F.
    Taber, D.
    Wade, J. L., III
    Hu, S.
    Ivy, S. P.
    Nichols, K.
    Dekker, A.
    Vokes, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] Analysis of HPV and ERCC1 in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Mehra, Ranee
    Egloff, Ann Marie
    Li, Shuli
    Yang, Donghua
    Wang, Lin
    Zhu, Fang
    Forastiere, Arlene A.
    Burtness, Barbara
    Argiris, Athanassios
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] MEDINDUCTION: Phase I trial evaluating the safety of durvalumab in combination with docetaxel, cisplatin and 5-FU (DCF) as induction therapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN)
    Even, C.
    Texier, M.
    Le Tourneau, C.
    Bahleda, R.
    Borcoman, E.
    Vinches, M.
    Toussaint, P.
    Marabelle, A.
    Breuskin, I.
    Cupissol, D.
    Fayette, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S682 - S683
  • [36] Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab (D) combined with weekly paclitaxel carboplatin in 1st-line in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible to cisplatin
    Fayette, J.
    Cropet, C.
    Gautier, J.
    Toullec, C.
    Vinches, M.
    Burgy, M.
    Iacob, M.
    Kaminsky-Forrett, M-C.
    Salas, S.
    Linot, B.
    Champagnac, A.
    Sondarjee, I.
    Pechery, A.
    Perol, D.
    Bourhis, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S623 - S623
  • [37] Randomized phase 2 trial of patritumab (P) or placebo (PBO) plus cetuximab (C) plus cisplatin (CIS) or carboplatin (CAR) for recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
    Harrington, Kevin J.
    Forster, Martin David
    Le Tourneau, Christophe
    Ariza, Jose
    Chen, Shuquan
    Greenberg, Jonathan
    Hirotani, Kenji
    Remenar, Eva
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN)
    Baghi, M
    Hambek, M
    Wagenblast, J
    May, A
    Wolfgang
    Gstoettner
    Knecht, R
    ANTICANCER RESEARCH, 2006, 26 (1B) : 585 - 590
  • [39] Monalizumab in combination with cetuximab post platinum and anti-PD-(L)1 in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Updated results from a phase II trial
    Fayette, J.
    Bauman, J.
    Salas, S.
    Colevas, D.
    Even, C.
    Cupissol, D.
    Posner, M. R.
    Lefebvre, G.
    Saada-Bouzid, E.
    Bernadach, M.
    Seiwert, T.
    Pearson, A.
    Messouak, S.
    Cornen, S. L.
    Andre, P.
    Rotolo, F.
    Boyer-Chammard, A.
    Cohen, R. B.
    ANNALS OF ONCOLOGY, 2020, 31 : S1450 - S1450
  • [40] The role of cetuximab maintenance after chemotherapy in patients with recurrent/metastatic squamous cell carcinoma of head and neck (R/M SCCHN): A retrospective analysis
    Wakasugi, T.
    Enokida, T.
    Nakanome, A.
    Yamazaki, T.
    Okano, S.
    Tahara, M.
    ANNALS OF ONCOLOGY, 2015, 26 : 95 - 95
12345